Limits...
A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent.

De Lorenzo C, Tedesco A, Terrazzano G, Cozzolino R, Laccetti P, Piccoli R, D'Alessio G - Br. J. Cancer (2004)

Bottom Line: A new human, compact antibody was engineered by fusion of a human, antitumour ErbB2-directed scFv with a human IgG1 Fc domain.This new immunoagent meets all criteria for a potential anticancer drug: it is human, hence poorly or not immunogenic; it binds selectively and with high affinity to target cells, on which it exerts an effective and selective antiproliferative action, including both antibody-dependent and complement-dependent cytotoxicity; it effectively inhibits tumour growth in vivo.Its compact molecular size should provide for an efficient tissue penetration, yet suitable to a prolonged serum half-life.

View Article: PubMed Central - PubMed

Affiliation: Department of Biological Chemistry, University of Naples Federico II, Via Mezzocannone 16, 80134 Naples, Italy.

ABSTRACT
A new human, compact antibody was engineered by fusion of a human, antitumour ErbB2-directed scFv with a human IgG1 Fc domain. Overexpression of the ErbB2 receptor is related to tumour aggressiveness and poor prognosis. This new immunoagent meets all criteria for a potential anticancer drug: it is human, hence poorly or not immunogenic; it binds selectively and with high affinity to target cells, on which it exerts an effective and selective antiproliferative action, including both antibody-dependent and complement-dependent cytotoxicity; it effectively inhibits tumour growth in vivo. Its compact molecular size should provide for an efficient tissue penetration, yet suitable to a prolonged serum half-life.

Show MeSH

Related in: MedlinePlus

In vivo suppression of tumour growth by Erb-hcAb. Tumour growth was followed in mice inoculated s.c. with 5 × 105 TUBO mammary carcinoma cells. Control animals (black circles) were treated with sterile PBS solution. Treated animals (white circles) were injected with Erb-hcAb, starting at day 15. Seven doses, each of 2.5 mg kg−1 of body weight, were administered at 72 h intervals.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2747711&req=5

fig4: In vivo suppression of tumour growth by Erb-hcAb. Tumour growth was followed in mice inoculated s.c. with 5 × 105 TUBO mammary carcinoma cells. Control animals (black circles) were treated with sterile PBS solution. Treated animals (white circles) were injected with Erb-hcAb, starting at day 15. Seven doses, each of 2.5 mg kg−1 of body weight, were administered at 72 h intervals.

Mentions: When administered to mice, TUBO cells induce tumours very similar to the alveolar-type human lobular mammary carcinomas (Di Carlo et al, 1999). As shown in Figure 4Figure 4


A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent.

De Lorenzo C, Tedesco A, Terrazzano G, Cozzolino R, Laccetti P, Piccoli R, D'Alessio G - Br. J. Cancer (2004)

In vivo suppression of tumour growth by Erb-hcAb. Tumour growth was followed in mice inoculated s.c. with 5 × 105 TUBO mammary carcinoma cells. Control animals (black circles) were treated with sterile PBS solution. Treated animals (white circles) were injected with Erb-hcAb, starting at day 15. Seven doses, each of 2.5 mg kg−1 of body weight, were administered at 72 h intervals.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2747711&req=5

fig4: In vivo suppression of tumour growth by Erb-hcAb. Tumour growth was followed in mice inoculated s.c. with 5 × 105 TUBO mammary carcinoma cells. Control animals (black circles) were treated with sterile PBS solution. Treated animals (white circles) were injected with Erb-hcAb, starting at day 15. Seven doses, each of 2.5 mg kg−1 of body weight, were administered at 72 h intervals.
Mentions: When administered to mice, TUBO cells induce tumours very similar to the alveolar-type human lobular mammary carcinomas (Di Carlo et al, 1999). As shown in Figure 4Figure 4

Bottom Line: A new human, compact antibody was engineered by fusion of a human, antitumour ErbB2-directed scFv with a human IgG1 Fc domain.This new immunoagent meets all criteria for a potential anticancer drug: it is human, hence poorly or not immunogenic; it binds selectively and with high affinity to target cells, on which it exerts an effective and selective antiproliferative action, including both antibody-dependent and complement-dependent cytotoxicity; it effectively inhibits tumour growth in vivo.Its compact molecular size should provide for an efficient tissue penetration, yet suitable to a prolonged serum half-life.

View Article: PubMed Central - PubMed

Affiliation: Department of Biological Chemistry, University of Naples Federico II, Via Mezzocannone 16, 80134 Naples, Italy.

ABSTRACT
A new human, compact antibody was engineered by fusion of a human, antitumour ErbB2-directed scFv with a human IgG1 Fc domain. Overexpression of the ErbB2 receptor is related to tumour aggressiveness and poor prognosis. This new immunoagent meets all criteria for a potential anticancer drug: it is human, hence poorly or not immunogenic; it binds selectively and with high affinity to target cells, on which it exerts an effective and selective antiproliferative action, including both antibody-dependent and complement-dependent cytotoxicity; it effectively inhibits tumour growth in vivo. Its compact molecular size should provide for an efficient tissue penetration, yet suitable to a prolonged serum half-life.

Show MeSH
Related in: MedlinePlus